纤维细胞生长因子20通过激活ErbB2改善心脏缩
Yunjie Chen1, Xuan Zhou1, Xu Wang2
1Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, China.
Heliyon
|September 25, 2024
概括
纤维细胞生长因子20 (FGF20) 通过激活红细胞白血病病毒瘤基因同源2 (ErbB2) 来保护心脏缩. 这种机制抑制了亡和氧化应激,这表明FGF20是治疗心脏病的潜在疗法.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 发展生物学 发展生物学
背景情况:
- 纤维细胞生长因子20 (FGF20) 对胚胎发育和心脏修复至关重要.
- 心脏缩是心力衰竭的重要危险因素.
研究的目的:
- 研究FGF20在心脏缩中的作用.
- 阐明FGF20对心脏的影响背后的分子机制.
主要方法:
- 心脏缩的体内和体外模型.
- 分析FGF20,红细胞白血病病毒性瘤基因同源2 (ErbB2),心房 natriuretic (ANP) 和大脑 natriuretic (BNP) 的表达.
- 评估心肌细胞亡和氧化应激.
- 在新生小鼠心肌细胞 (NRCMs) 中使用ErbB2抑制剂拉帕蒂尼布.
主要成果:
- 在实验模型中,FGF20治疗改善了心脏缩.
- FGF20上调了ErbB2的表达,这与心脏缩标志物 (ANP,BNP) 相反相关.
- FGF20保护心肌细胞免受亡和氧化应激.
- 拉帕提尼布治疗阻断了FGF20的抗增高作用,并扭转了其保护性益处.
结论:
- 通过激活ErbB2.2,FGF20可以预防心脏缩.
- FGF20的保护作用包括抑制亡和氧化应激.
- FGF20代表了管理心脏缩的潜在治疗策略.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396


